- Home
- SNY vs UBS Comparison
SNY vs UBS Comparison
Compare SNY & UBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- UBS
- Stock Information
- Founded
- SNY 1994
- UBS 1862
- Country
- SNY France
- UBS Switzerland
- Employees
- SNY N/A
- UBS N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- UBS Major Banks
- Sector
- SNY Health Care
- UBS Finance
- Exchange
- SNY Nasdaq
- UBS Nasdaq
- Market Cap
- SNY 127.2B
- UBS 104.3B
- IPO Year
- SNY N/A
- UBS N/A
- Fundamental
- Price
- SNY $47.86
- UBS $30.43
- Analyst Decision
- SNY Buy
- UBS Buy
- Analyst Count
- SNY 2
- UBS 3
- Target Price
- SNY $62.50
- UBS N/A
- AVG Volume (30 Days)
- SNY 2.3M
- UBS 2.8M
- Earning Date
- SNY 07-24-2025
- UBS 07-30-2025
- Dividend Yield
- SNY 4.62%
- UBS 2.93%
- EPS Growth
- SNY 39.56
- UBS N/A
- EPS
- SNY 5.45
- UBS 1.51
- Revenue
- SNY $48,817,552,946.00
- UBS $47,760,000,000.00
- Revenue This Year
- SNY $3.39
- UBS $1.11
- Revenue Next Year
- SNY $7.05
- UBS $2.42
- P/E Ratio
- SNY $8.78
- UBS $18.63
- Revenue Growth
- SNY N/A
- UBS 9.69
- 52 Week Low
- SNY $45.80
- UBS $25.75
- 52 Week High
- SNY $60.12
- UBS $35.84
- Technical
- Relative Strength Index (RSI)
- SNY 36.40
- UBS 40.16
- Support Level
- SNY $47.42
- UBS $31.87
- Resistance Level
- SNY $51.04
- UBS $32.31
- Average True Range (ATR)
- SNY 0.66
- UBS 0.45
- MACD
- SNY -0.18
- UBS -0.25
- Stochastic Oscillator
- SNY 12.15
- UBS 1.56
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
About UBS UBS Group AG Registered
The core of UBS is its global wealth management business focusing on high and ultra-high-net-worth individuals. UBS is also a conventional retail and commercial bank in its Swiss home market. Its investment bank and asset management businesses support its wealth management operations, but also leverage its strength in wealth management to serve third-party clients.